Great people form the core of any great organization. PreludeDx is always looking for highly qualified people with a passion for improving the lives of cancer patients. We will periodically post information about openings but are always interested in hearing from those who believe in our mission and values.
Assessment of a poor response-type (RSt) signature with breast conserving surgery to potentially identify women at elevated risk after surgery and radiation.
284 eligible patients with biomarker data and 102 received hormone therapy and 233 received radiation therapy. The RSt biosignature was calculated using specific biomarkers scored by board certified pathologists in a CLIA certified laboratory.
A new biosignature identified a Poor Response Type in women with early stage invasive breast cancer
Women with a Poor Response Type had high risk for ispilateral breast events after BCS + RT
Women with a Good Response Type had an excellent outcome after BCS + RT
By Marv Kogan|2020-11-19T13:53:50-06:00November 6th, 2020|
A multi-biomarker prognostic risk assessment was developed using cross-validation modeling within two large patient cohorts treated with and without RT after BCS.
Patients were from Uppsala University Hospital (UUH), diagnosed 1986-2004, and University of Massachusetts (UMass), diagnosed 1999-2008, had been treated with BCS with (56%) or without (44%) adjuvant RT.
The biomarker-based risk stratification identified patients at risk for invasive ipsilateral breast events in cross-validation.
Patients with low biomarker based risk had a 10-year invasive recurrence risk without RT that is low and similar to that with RT.
By Prelude|2020-06-26T14:29:29-05:00April 30th, 2016|
To develop and blindly validate a multi-marker risk stratification test in DCIS patients treated with BCS.
Separate models to predict DCIS and invasive event risk were developed using statistical pattern recognition and modeling methods on UUH patients treated with BCS in the absence of adjuvant therapy (n=200). In addition, an “overall” risk model was created by combining the DCIS and invasive models.
This study indicates that the present approach to risk stratification modeling can accurately identify patients at risk for DCIS or invasive events after a primary DCIS diagnosis.
The models presented here were the basis of a comprehensive multi-marker panel undergoing formal validation.
By Prelude|2020-06-26T14:31:02-05:00March 12th, 2014|